Neurobiology of Aging
Volume 32, Issue 10 , Pages 1839-1848 , October 2011

Transcriptional profile of Parkinson blood mononuclear cells with LRRK2 mutation

  • Eugénie Mutez

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • CHU, Department of Neurology and Movement Disorders, F-59000 Lille, France
    • ,
  • Lydie Larvor

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • ,
  • Frédéric Leprêtre

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • INSERM U837 – JPArc, F-59000 Lille, France
    • ,
  • Vincent Mouroux

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • ,
  • Dorota Hamalek

      Affiliations

    • Geriatrics Centre, F-59290 Wasquehal, France
    • ,
  • Jean-Pierre Kerckaert

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • INSERM U837 – JPArc, F-59000 Lille, France
    • ,
  • Jordi Pérez-Tur

      Affiliations

    • Unit of Molecular Genetics, Biomedical Institute – CSIC, E-46010 Valencia, Spain
    • ,
  • Nawal Waucquier

      Affiliations

    • CHU, Department of Neurology and Movement Disorders, F-59000 Lille, France
    • ,
  • Christel Vanbesien-Mailliot

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • USTL, Department of Neurosciences, F-59650 Villeneuve d’Ascq, France
    • ,
  • Aurélie Duflot

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • ,
  • David Devos

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • CHU, Department of Neurology and Movement Disorders, F-59000 Lille, France
    • ,
  • Luc Defebvre

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • CHU, Department of Neurology and Movement Disorders, F-59000 Lille, France
    • ,
  • Alexandre Kreisler

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • CHU, Department of Neurology and Movement Disorders, F-59000 Lille, France
    • ,
  • Bernard Frigard

      Affiliations

    • Geriatrics Centre, F-59290 Wasquehal, France
    • ,
  • Alain Destée

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • CHU, Department of Neurology and Movement Disorders, F-59000 Lille, France
    • ,
  • Marie-Christine Chartier-Harlin

      Affiliations

    • Univ Lille Nord de France, F-59000 Lille, France
    • UDSL, EA2683 MENRT, IFR114 IMPRT – IRCL-JPArc, F-59000 Lille, France
    • Corresponding Author InformationCorresponding author at: EA2683 MENRT, IRCL, JPArc, Place de Verdun, F-59045 Lille Cedex, France. Tel.: +33 0320 169 222; fax: +33 0320 169 229.

Received 19 February 2009 ,Revised 7 October 2009 ,Accepted 27 October 2009.

References 

  1. Abou-Sleiman PM, Muqit MM, Woods NW. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 2006;7(3):207–219
  2. Amenta F, Bronzetti E, Cantalamessa F, El-Assouad D, Felici L, Ricci A, et al. Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J. Neuroimmunol. 2001;117(1–2):133–142
  3. Anglade P, Vyas S, Javoy-Agid F, Herrero MT, Michel PP, Marquez J, et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson's disease. Histol. Histopathol. 1997;12(1):25–31
  4. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, et al. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 2006;60(5):557–569
  5. Blandini F, Sinforiani E, Pacchetti C, Samuele A, Bazzini E, Zangaglia R, et al. Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology. 2006;66(4):529–534
  6. Brochard V, Combadière B, Prigent A, Laouar Y, Perrin A, Beray-Berthat V, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J. Clin. Invest. 2009;119(1):182–192
  7. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, Desai BS, et al. 6-Hydroxydopamine-induced alterations in blood–brain barrier permeability. Eur. J. Neurosci. 2005;22(5):1158–1168
  8. Chin MH, Qian WJ, Wang H, Petyuk VA, Bloom JS, Sforza DM, et al. Mitochondrial dysfunction, oxidative stress, and apoptosis revealed by proteomic and transcriptomic analyses of the striata in two mouse models of Parkinson's disease. J. Proteome Res. 2008;7(2):666–677
  9. Ferrer I, Blanco R, Carmona M, Puig B, Barrachina M, Gomez C, et al. Active, phosphorylation-dependant mitogen-activated protein kinase (MAPK/ERK), stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK), and p38 kinase expression in Parkinson's disease and dementia with Lewy bodies. J. Neural Transm. 2001;108(12):1383–1396
  10. Gallo KA, Johnson G. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nat. Rev. Mol. Cell. Biol. 2002;3(9):663–672
  11. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch. Neurol. 1999;56(1):33–39
  12. Grünblatt E, Mandel S, Jacob-Hirsch J, Zeligson S, Amariglo N, Rechavi G, et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitine–proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. 2004;111(12):1543–1573
  13. Häbig K, Walter M, Poths S, Riess O, Bonin M. RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics. 2008;9(2):83–94
  14. Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, et al. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case–control study. Lancet Neurol. 2008;7(7):583–590
  15. Hirsch EC. How to improve neuroprotection in Parkinson's disease?. Parkinsonism Relat. Disord. 2007;13(S3):S332–S335
  16. Ho CC, Rideout HJ, Ribe E, Troy CM, Dauer WT. The Parkinson disease protein leucine-rich repeat kinase 2 transduces death signals via Fas-associated protein with death domain and caspase-8 in a cellular model of neurodegeneration. J. Neurosci. 2009;29(4):1011–1016
  17. Huot J. Ephrin signalling in axon guidance. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2004;28(5):813–818
  18. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 2007;16(11):1319–1326
  19. Imam SZ, Newport GD, Islam F, Slikker W, Ali SF. Selenium, an antioxidant, protects against methamphetamine-induced dopaminergic neurotoxicity. Brain Res. 1999;818(2):575–578
  20. Jaleel M, Nichols RJ, Deak M, Campbell DG, Gillardon F, Knebel A, et al. LRRK2 phosphorylates moesin at Thr558: characterisation of how Parkinson's disease mutants affect kinase activity. Biochem. J. 2007;405(2):307–317
  21. Kortekaas R, Leenders KL, van Oostrom JC, Vaalburg W, Bart J, Willemsen AT, et al. Blood–brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 2005;57(2):176–179
  22. Laihinen A, Ruottinen H, Rinne JO, Haaparanta M, Bergman J, Solin O, et al. Risk for Parkinson's disease: twin studies for the detection of asymptomatic subjects using [18F]6-fluorodopa PET. J. Neurol. 2000;247(S2):II10–13
  23. Lesnick TG, Papapetropoulos S, Mash DC, Ffrench-Mullen J, Shehadeh L, de Andrade M, et al. A genomic pathway approach to a complex disease: axon guidance and Parkinson disease. PLoS Genet. 2007;3(6):984–995
  24. Leveugle B, Faucheux BA, Bouras C, Nillesse N, Spik G, Hirsch EC, et al. Cellular distribution of the iron-binding protein lactotransferrin in the mesencephalon of Parkinson's disease cases. Acta Neuropathol. 1996;91(6):566–572
  25. Lin L, Lesnick TG, Maraganore DM, Isacson O. Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics. Trends Neurosci. 2009;
  26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT method. Methods. 2001;25(4):402–408
  27. Mata IF, Wedemeyer WJ, Farrer MJ, Taylor JP, Gallo KA. LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 2006;29(5):286–293
  28. MacLeod D, Dowman J, Hammond R, Leete T, Inoue K, Abeliovich A. The familial parkinsonian gene LRRK2 regulates neurite process morphology. Neuron. 2006;52(4):587–593
  29. McGeer P, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology. 1988;38(8):1285–1291
  30. Miklossy J, Doudet DD, Schwab C, Yu S, McGeer EG, McGeer PL. Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys. Exp. Neurol. 2006;197(2):275–283
  31. Miller RM, Kiser GL, Kaysser-Kranich TM, Lockner RJ, Palaniappan C, Federoff HJ. Robust deregulation of gene expression in substantia nigra and striatum in Parkinson's disease. Neurobiol. Dis. 2006;21(2):305–313
  32. Monahan AJ, Warren M, Carvey PM. Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplant. 2008;17(4):363–372
  33. Mount MP, Lira A, Grimes D, Smith PD, Faucher S, Slack R, et al. Involvement of interferon-γ in microglial-mediated loss of dopaminergic neurons. J. Neurosci. 2007;27(12):3328–3337
  34. Plowey ED, Cherra SJ, Liu YJ, Chu CT. Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 2008;105(3):1048–1056
  35. Reynolds AD, Banerjee R, Liu J, Gendelman HE, Mosley RL. Neuroprotective activities of CD4+ CD25+ regulatory T cells in an animal model of Parkinson's disease. J. Leukoc. Biol. 2007;82(5):1083–1094
  36. Sakaguchi-Nakashima A, Meir J, Jin Y, Matsumoto K, Hisamoto N. LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol. 2007;17(7):592–598
  37. Scherzer CR, Eklund AC, Morse LJ, Liao Z, Locascio JJ, Fefer D, et al. Molecular markers of early Parkinson's disease based on gene expression in blood. Proc. Natl. Acad. Sci. U.S.A. 2007;104(3):955–960
  38. Shinde S, Pasupathy K. Respiratory-chain enzyme activities in isolated mitochondria of lymphocytes from patients with Parkinson's disease: preliminary study. Neurol. India. 2006;54(4):390–393
  39. Srinivasan BS, Doostzadeh J, Absalan F, Mohandessi S, Jalili R, Bigdeli S, et al. Whole genome survey of coding SNPs reveals a reproducible pathway determinant of Parkinson disease. Hum. Mutat. 2009;30(2):228–238
  40. Theodosiou A, Smith A, Gillieron C, Arkinstall S, Ashworth A. MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene. 1999;18(50):6981–6988
  41. Tolosa E, Compta Y, Gaig C. The premotor phase of Parkinson's disease. Parkinsonism Relat. Disord. 2007;13(Suppl.):S2–S7
  42. Vila M, Ramonet D, Perier C. Mitochondrial alterations in Parkinson's disease: new clues. J. Neurochem. 2008;107(2):317–328
  43. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, et al. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl. Acad. Sci. U.S.A. 2005;102(46):16842–16847
  44. White LR, Toft M, Kvam SN, Farrer MJ, Aasly JO. MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J. Neurosci. Res. 2007;85(6):1288–1294
  45. Xia XG, Harding T, Weller M, Bieneman A, Uney JB, Sculz JB. Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease. Proc. Natl. Acad. Sci. U.S.A. 2001;98(18):10433–10438
  46. Zimprich A, Biskup S, Leitner P, Lichtner P, Farrer M, Lincoln S, et al. Mutation in LRRK2 causes autosomal dominant parkinsonism with pleomorphic pathology. Neuron. 2004;44(4):601–607
  47. Zhang Y, James M, Middleton FA, Davis RL. Transcriptional analysis of multiple brain regions in Parkinson's disease supports the involvement of specific protein processing, energy metabolism and signalling pathways, and suggests novel disease mechanisms. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2005;137B(1):5–16

PII: S0197-4580(09)00357-1

doi: 10.1016/j.neurobiolaging.2009.10.016

Neurobiology of Aging
Volume 32, Issue 10 , Pages 1839-1848 , October 2011

Article Tools

* Image Usage & Resolution